Global Research and Patient Priorities – Pediatric and Rare Liver Diseases News
Kristin Hatcher, Director of GLI’s Pediatric and Rare Liver Disease Program, joined U.S. and global pharmaceutical leaders for a powerful discussion on gaps in drug development and the critical need to include lived patient experience in both rare and common diseases.
Culturally Relevant Tools to Increase Hepatitis B Screening in Asian American Communities
Infection with hepatitis B poses a serious risk to the health of many Americans – especially in certain groups with high risk, including Asian Americans and Asian-American immigrants. Research has found that, to support universal adult screening recommendations, culturally- and linguistically- appropriate educational tools can increase the rate of screening.
Global Liver Institute Leads Efforts in Urging FDA to Recognize Patient-Defined Progress in Drug Development
At the Global Liver Institute, we believe that it all starts with a patient because only they define what progress means to their lives. By elevating their lived experiences, we ensure that science, policy, and care move in the direction that matters most: toward earlier answers, more options, and a better standard of care.
TROA Reintroduced, Veterans Health Advances, Hep C Bill Introduced, and Senate Considers Medicaid Cuts – Liver Health Policy Update
The House passed H.R. 1, the One Big, Beautiful Bill Act, sending the budget reconciliation package to the Senate.
GLI Works With Congress to Protect Veterans’ Health
Global Liver Institute (GLI), in close coordination with congressional staff, has worked tirelessly to ensure that veterans diagnosed with NASH/MASH have no barriers to their care and treatment.